vs

Side-by-side financial comparison of ASPEN AEROGELS INC (ASPN) and RECURSION PHARMACEUTICALS, INC. (RXRX). Click either name above to swap in a different company.

ASPEN AEROGELS INC is the larger business by last-quarter revenue ($41.3M vs $35.5M, roughly 1.2× RECURSION PHARMACEUTICALS, INC.). ASPEN AEROGELS INC runs the higher net margin — -176.4% vs -304.2%, a 127.9% gap on every dollar of revenue. On growth, RECURSION PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (681.7% vs -66.4%). ASPEN AEROGELS INC produced more free cash flow last quarter ($13.7M vs $-47.3M). Over the past eight quarters, RECURSION PHARMACEUTICALS, INC.'s revenue compounded faster (60.5% CAGR vs -33.9%).

Aspen Aerogels Inc is a leading manufacturer of high-performance aerogel-based insulation and thermal management materials. It serves core sectors including renewable energy, oil and gas infrastructure, aerospace, commercial construction and industrial manufacturing, with key markets across North America, Europe and Asia-Pacific. Its products are prized for superior thermal resistance, fire safety and lightweight performance for harsh operating conditions.

Recursion Pharmaceuticals is a clinical-stage biotechnology company that combines artificial intelligence and large-scale high-throughput biological experimentation to discover and develop innovative therapies for rare diseases, oncology, inflammatory disorders, and other areas of unmet medical need. It primarily operates in North America and partners with global biopharmaceutical firms to advance its robust therapeutic pipeline.

ASPN vs RXRX — Head-to-Head

Bigger by revenue
ASPN
ASPN
1.2× larger
ASPN
$41.3M
$35.5M
RXRX
Growing faster (revenue YoY)
RXRX
RXRX
+748.2% gap
RXRX
681.7%
-66.4%
ASPN
Higher net margin
ASPN
ASPN
127.9% more per $
ASPN
-176.4%
-304.2%
RXRX
More free cash flow
ASPN
ASPN
$61.0M more FCF
ASPN
$13.7M
$-47.3M
RXRX
Faster 2-yr revenue CAGR
RXRX
RXRX
Annualised
RXRX
60.5%
-33.9%
ASPN

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ASPN
ASPN
RXRX
RXRX
Revenue
$41.3M
$35.5M
Net Profit
$-72.9M
$-108.1M
Gross Margin
-55.5%
59.8%
Operating Margin
-170.3%
-304.8%
Net Margin
-176.4%
-304.2%
Revenue YoY
-66.4%
681.7%
Net Profit YoY
-741.7%
39.6%
EPS (diluted)
$-0.87
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ASPN
ASPN
RXRX
RXRX
Q4 25
$41.3M
$35.5M
Q3 25
$73.0M
$5.2M
Q2 25
$78.0M
$19.2M
Q1 25
$78.7M
$14.7M
Q4 24
$123.1M
$4.5M
Q3 24
$117.3M
$26.1M
Q2 24
$117.8M
$14.4M
Q1 24
$94.5M
$13.8M
Net Profit
ASPN
ASPN
RXRX
RXRX
Q4 25
$-72.9M
$-108.1M
Q3 25
$-6.3M
$-162.3M
Q2 25
$-9.1M
$-171.9M
Q1 25
$-301.2M
$-202.5M
Q4 24
$11.4M
$-178.9M
Q3 24
$-13.0M
$-95.8M
Q2 24
$16.8M
$-97.5M
Q1 24
$-1.8M
$-91.4M
Gross Margin
ASPN
ASPN
RXRX
RXRX
Q4 25
-55.5%
59.8%
Q3 25
28.5%
-183.8%
Q2 25
32.4%
-4.9%
Q1 25
29.0%
-48.0%
Q4 24
38.3%
-181.4%
Q3 24
41.8%
53.7%
Q2 24
43.8%
36.2%
Q1 24
37.2%
19.1%
Operating Margin
ASPN
ASPN
RXRX
RXRX
Q4 25
-170.3%
-304.8%
Q3 25
-4.6%
-3327.6%
Q2 25
-6.6%
-916.8%
Q1 25
-380.2%
-1297.9%
Q4 24
12.0%
-4042.4%
Q3 24
14.8%
-377.1%
Q2 24
17.0%
-697.4%
Q1 24
2.6%
-698.4%
Net Margin
ASPN
ASPN
RXRX
RXRX
Q4 25
-176.4%
-304.2%
Q3 25
-8.7%
-3135.3%
Q2 25
-11.6%
-894.2%
Q1 25
-382.7%
-1373.3%
Q4 24
9.2%
-3935.5%
Q3 24
-11.1%
-367.5%
Q2 24
14.3%
-676.6%
Q1 24
-1.9%
-662.4%
EPS (diluted)
ASPN
ASPN
RXRX
RXRX
Q4 25
$-0.87
$-0.17
Q3 25
$-0.08
$-0.36
Q2 25
$-0.11
$-0.41
Q1 25
$-3.67
$-0.50
Q4 24
$0.15
$-0.56
Q3 24
$-0.17
$-0.34
Q2 24
$0.21
$-0.40
Q1 24
$-0.02
$-0.39

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ASPN
ASPN
RXRX
RXRX
Cash + ST InvestmentsLiquidity on hand
$156.9M
$743.3M
Total DebtLower is stronger
$65.5M
$9.6M
Stockholders' EquityBook value
$235.5M
$1.1B
Total Assets
$406.7M
$1.5B
Debt / EquityLower = less leverage
0.28×
0.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ASPN
ASPN
RXRX
RXRX
Q4 25
$156.9M
$743.3M
Q3 25
$150.7M
$659.8M
Q2 25
$167.6M
$525.1M
Q1 25
$192.0M
$500.5M
Q4 24
$220.9M
$594.4M
Q3 24
$113.5M
$427.6M
Q2 24
$91.4M
$474.3M
Q1 24
$101.5M
$296.3M
Total Debt
ASPN
ASPN
RXRX
RXRX
Q4 25
$65.5M
$9.6M
Q3 25
$70.1M
$11.9M
Q2 25
$77.3M
$14.2M
Q1 25
$95.4M
$16.4M
Q4 24
$95.0M
$19.0M
Q3 24
$93.7M
$20.5M
Q2 24
$22.9M
Q1 24
Stockholders' Equity
ASPN
ASPN
RXRX
RXRX
Q4 25
$235.5M
$1.1B
Q3 25
$305.7M
$1.0B
Q2 25
$308.8M
$919.1M
Q1 25
$314.8M
$933.9M
Q4 24
$614.7M
$1.0B
Q3 24
$507.6M
$524.6M
Q2 24
$517.8M
$584.4M
Q1 24
$491.2M
$401.2M
Total Assets
ASPN
ASPN
RXRX
RXRX
Q4 25
$406.7M
$1.5B
Q3 25
$491.4M
$1.4B
Q2 25
$525.1M
$1.3B
Q1 25
$555.0M
$1.3B
Q4 24
$895.1M
$1.4B
Q3 24
$782.6M
$726.5M
Q2 24
$748.6M
$775.9M
Q1 24
$698.0M
$557.8M
Debt / Equity
ASPN
ASPN
RXRX
RXRX
Q4 25
0.28×
0.01×
Q3 25
0.23×
0.01×
Q2 25
0.25×
0.02×
Q1 25
0.30×
0.02×
Q4 24
0.15×
0.02×
Q3 24
0.18×
0.04×
Q2 24
0.04×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ASPN
ASPN
RXRX
RXRX
Operating Cash FlowLast quarter
$16.1M
$-46.1M
Free Cash FlowOCF − Capex
$13.7M
$-47.3M
FCF MarginFCF / Revenue
33.1%
-133.1%
Capex IntensityCapex / Revenue
6.0%
3.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-4.6M
$-378.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ASPN
ASPN
RXRX
RXRX
Q4 25
$16.1M
$-46.1M
Q3 25
$15.0M
$-117.4M
Q2 25
$-3.9M
$-76.4M
Q1 25
$5.6M
$-132.0M
Q4 24
$35.7M
$-115.4M
Q3 24
$20.8M
$-59.2M
Q2 24
$6.8M
$-82.2M
Q1 24
$-17.7M
$-102.3M
Free Cash Flow
ASPN
ASPN
RXRX
RXRX
Q4 25
$13.7M
$-47.3M
Q3 25
$5.9M
$-117.6M
Q2 25
$-16.8M
$-79.6M
Q1 25
$-7.4M
$-133.8M
Q4 24
$20.9M
$-116.7M
Q3 24
$-50.0K
$-63.8M
Q2 24
$-18.0M
$-83.4M
Q1 24
$-43.6M
$-109.0M
FCF Margin
ASPN
ASPN
RXRX
RXRX
Q4 25
33.1%
-133.1%
Q3 25
8.1%
-2272.5%
Q2 25
-21.6%
-413.9%
Q1 25
-9.4%
-907.4%
Q4 24
17.0%
-2567.7%
Q3 24
-0.0%
-244.6%
Q2 24
-15.3%
-578.5%
Q1 24
-46.1%
-789.9%
Capex Intensity
ASPN
ASPN
RXRX
RXRX
Q4 25
6.0%
3.5%
Q3 25
12.5%
4.7%
Q2 25
16.5%
16.4%
Q1 25
16.5%
12.4%
Q4 24
12.0%
28.6%
Q3 24
17.7%
17.5%
Q2 24
21.1%
8.2%
Q1 24
27.4%
48.2%
Cash Conversion
ASPN
ASPN
RXRX
RXRX
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
3.14×
Q3 24
Q2 24
0.41×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ASPN
ASPN

Energy Industrial$14.5M35%
Other$13.9M34%
Thermal Barrier$12.9M31%

RXRX
RXRX

Segment breakdown not available.

Related Comparisons